0001141103FALSE00011411032024-05-142024-05-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 14, 2024

Cross Country Healthcare, Inc.
(Exact name of registrant as specified in its charter)

6551 Park of Commerce Boulevard, N.W., Boca Raton, FL 33487
(Address of Principal Executive Office) (Zip Code)
(561) 998-2232
(Registrant’s telephone number, including area code)
Not Applicable

(Former name or former address, if changed since last report)

Common stock, par value $0.0001 per share          CCRN            The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

(a) On May 14, 2024, the Company held its Annual Meeting of Stockholders (“Annual Meeting”).

(b) The following items of business were voted upon by stockholders at the Annual Meeting:

(i) A proposal to elect the directors listed below for a one-year term ending in 2025 or until their successors are duly

elected and qualified was approved with the following vote:

(ii) The ratification of the appointment of Deloitte & Touche as the Company's independent registered public

accounting firm for the fiscal year ending December 31, 2024 was approved as follows:

For						Against						Abstentions						Broker Non-Votes
31,129,700						495,366						10,704						0

(iii) The compensation of named executive officers was approved, on an advisory (non-binding) basis, by the votes set

forth below:

For						Against						Abstentions						Broker Non-Votes
28,173,257						1,401,470						126,259						1,934,784

(iv) The approval of the Company's 2024 Omnibus Incentive Plan was approved as follows:

For						Against						Abstentions						Broker Non-Votes
27,695,632						1,872,698						132,656						1,934,784

(d) Exhibits

104     Cover Page Interactive Data File (embedded within the Inline XBRL document)

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.